MiNK Therapeutics, Eli Lilly and Company, Verona Pharma PLC American Depositary Share, Thermo Fisher Scientific, and AbbVie are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are equity shares in companies that research, develop, manufacture and market prescription drugs and medical therapies. Their value is driven by factors such as clinical trial results, regulatory approvals, patent expirations and shifts in healthcare policy. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
MiNK Therapeutics (INKT)
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.
INKT traded up $55.32 during trading on Friday, reaching $63.05. The stock had a trading volume of 37,927,318 shares, compared to its average volume of 168,640. The stock's 50 day moving average is $7.32 and its two-hundred day moving average is $8.02. The company has a market capitalization of $251.33 million, a price-to-earnings ratio of -24.07 and a beta of 0.19. MiNK Therapeutics has a one year low of $4.56 and a one year high of $72.94.
Read Our Latest Research Report on INKT
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Shares of LLY traded down $5.03 during mid-day trading on Friday, reaching $785.62. The company had a trading volume of 1,526,490 shares, compared to its average volume of 3,661,948. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. The company has a market capitalization of $744.56 billion, a price-to-earnings ratio of 63.90, a price-to-earnings-growth ratio of 1.15 and a beta of 0.40. The firm has a 50-day moving average price of $767.03 and a 200 day moving average price of $800.01. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53.
Read Our Latest Research Report on LLY
Verona Pharma PLC American Depositary Share (VRNA)
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
VRNA stock traded up $0.01 during midday trading on Friday, hitting $104.86. The company's stock had a trading volume of 8,685,464 shares, compared to its average volume of 1,598,884. Verona Pharma PLC American Depositary Share has a 12 month low of $17.96 and a 12 month high of $104.99. The firm's 50-day moving average is $83.25 and its 200-day moving average is $67.25. The company has a current ratio of 8.86, a quick ratio of 8.73 and a debt-to-equity ratio of 1.07. The company has a market cap of $8.93 billion, a PE ratio of -52.43 and a beta of 0.24.
Read Our Latest Research Report on VRNA
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Shares of TMO stock traded up $4.26 on Friday, reaching $434.99. The stock had a trading volume of 1,502,633 shares, compared to its average volume of 2,400,873. The stock has a market cap of $164.20 billion, a P/E ratio of 25.52, a price-to-earnings-growth ratio of 2.23 and a beta of 0.77. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77. Thermo Fisher Scientific has a 1 year low of $385.46 and a 1 year high of $627.88. The company has a 50 day simple moving average of $409.16 and a 200 day simple moving average of $477.24.
Read Our Latest Research Report on TMO
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
NYSE ABBV traded down $2.77 during trading hours on Friday, hitting $192.23. 2,803,271 shares of the company's stock traded hands, compared to its average volume of 7,021,396. The business's fifty day moving average price is $187.13 and its two-hundred day moving average price is $188.90. The firm has a market capitalization of $339.55 billion, a P/E ratio of 81.82, a P/E/G ratio of 1.29 and a beta of 0.48. AbbVie has a 52 week low of $163.81 and a 52 week high of $218.66. The company has a current ratio of 0.76, a quick ratio of 0.64 and a debt-to-equity ratio of 44.14.
Read Our Latest Research Report on ABBV
Further Reading
Before you consider MiNK Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiNK Therapeutics wasn't on the list.
While MiNK Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
